"Which leads me to wonder.... could BETonMACE miss its endpoints, but still show significant effects on cognition?"

In the case that significant effects are found in the CKD and/or cognition BETonMACE sub-studies, but the primary MACE endpoint is missed, then my understanding is that these are only considered exploratory findings not supportive of NDA or MAA approval by the FDA or EMA. In other words, apabetalone could not be approved for use but Resverlogix would have promising cognition and/or CKD results to justify follow up clinical trials necessary to support drug approval.

BearDownAZ